CHU De Martinique

The department concentrates on viral and bacterial infections, including HIV, early syphilis, and Staphylococcus aureus bacteremia. Trials aim to evaluate new antimicrobial regimens and preventive strategies.

• Comparative effectiveness of doxycycline versus benzathine penicillin for early syphilis
• Impact of treatment strategies on mortality in Staphylococcus aureus bloodstream infection
• Long‑term outcomes of antiretroviral therapy optimization in HIV patients

Research supports evidence‑based guidelines and improves patient care across the Caribbean region.

Investigations target advanced and high‑risk prostate cancer, testing novel hormonal agents, radiotherapy combinations, and treatment de‑escalation approaches.

• Darolutamide with stereotactic radiotherapy in high‑risk disease
• Apalutamide added to salvage radiotherapy after prostatectomy
• Beta‑blocker discontinuation effects on heart function in prostate cancer patients receiving therapy

These studies seek to extend survival and reduce treatment‑related toxicity.

Trials address malignancies of the colon, pancreas, and neuroendocrine system, such as colon cancer and gastro‑entero‑pancreatic neuroendocrine carcinoma, focusing on adjuvant chemotherapy and personalized medicine.

• Circulating tumor DNA‑guided adjuvant FOLFOX in stage II colon cancer
• mFOLFIRINOX versus platinum‑etoposide in metastatic neuroendocrine carcinoma
• Adjuvant chemotherapy outcomes in elderly patients after stage III colon resection

The goal is to improve disease‑free survival and tailor therapy to molecular risk profiles.

Research includes heart failure management and rare protein‑misfolding disorders like transthyretin amyloidosis with cardiomyopathy, evaluating drug efficacy and safety.

• Beta‑blocker withdrawal in recovered heart failure patients
• Acoramidis to prevent ATTR in asymptomatic carriers
• Nucresiran effects on mortality and cardiovascular events in ATTR‑CM

Findings aim to reduce cardiac complications and expand therapeutic options for amyloid disease.

The site conducts studies on immune‑mediated conditions such as lupus nephritis, exploring steroid‑sparing regimens and novel biologics.

• Obinutuzumab plus MMF versus corticosteroids for lupus nephritis
• Evaluation of immune modulation in severe acute pain management
• Assessment of long‑term renal response without oral corticosteroids

These trials strive to lessen long‑term organ damage while maintaining disease control.

Dermatologic research includes acne treatment in diverse populations, assessing efficacy of oral isotretinoin compared with standard care.

• Early isotretinoin therapy in moderate acne for skin‑of‑color patients
• Quality‑of‑life outcomes linked to acne severity reduction
• Comparative safety profile of isotretinoin versus conventional therapies

The work supports better therapeutic choices for patients with skin concerns.